

#### ICMR - NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

Contact: 033 2370 5533/4478/0448; 033 2353 7469; Ext. 121/190 Email: vrdln.niced@gmail.com

## INFORMATION REGARDING TESTING OF SAMPLES FOR NOVEL CORONA VIRUS SARS-CoV-2

- ICMR-NICED has been recognized by Govt. of India for testing of COVID-19.
- ICMR-NICED presently caters to the states of Bihar, Jharkhand, Meghalaya, Odisha, Sikkim and West Bengal.
- The collected clinical samples should be routed through the corresponding State Health Department.
- Contact persons for testing at Regional VRDL, ICMR-NICED:
   Dr. Hasina Banu, Mob. 9674666199; Dr. Agniva Majumdar, Mob. 9433756755
- Contact persons at State Health Department, West Bengal (www.wbhealth.gov.in):
   Dr. Dipankar Majhi, Dr. Bikas Mondal
- Each sample should be accompanied by properly filled in Specimen Referral Form (Annexure I)
- Guidelines regarding sample collection, packaging and transport (Annexure II).
- Guidelines for general preventive measures (Annexure III).

\*\*\*

## ICMR- National Institute of Virology, Pune Specimen Referral Form for 2019 Novel Coronavirus (2019-nCoV)

	INSTRUCTIONS:								
Inform the local / district / state health authorities, especially surveillance officer for further guidance.									
Seek guidance on requirements for the clinical specimen collection and transport from nodal officer.  The first seek guidance on requirements for the clinical specimen collection and transport from nodal officer.									
This form may be filled in and shared with the IDSP and also ICMR-NIV nodal officer in advance.  PERSON DETAILS									
				A many Manager A	4 JL C L MA-I-T				
Name of patient: Address:			Age:Years	Age:YearsMonth Gender: Male Female					
City:				Date of birth:	Date of birth:/ (dd/mm/yyyy)				
State:				Mobile/phone:					
State			•••••	Email:	•				
<b>EXPOSURE HISTO</b>	EXPOSURE HISTORY (2 WEEKS BEFORE THE ONSET OF SYMPTOMS)								
Recent stay/trave			na):Yes		ravel duration with da				
History of visit to v			Yes 🔃	No From:/ to:/					
Close contact with			Yes 🔃	=	·				
Recent travel to a	•	•	Yes□						
			involved in	managing patients					
Hospitalization da				Discharge date: .	//				
CLINICAL SYMPTO				T =					
Date of onset of sy		//							
Symptoms	Yes No	Symptoms	Yes No		_ ′ ′	es No			
Fever at evaluation	<u>n</u> 🗌 📗	<u>Cough</u>	닏늗	Diarrhoea 📙	Abdominal pair				
<u>History of fever</u>		Breathless		Nausea	☐ Vomiting	님 님			
Chart main		Sore throa	ᆥᅟᅟ 무	Body-ache	☐ Haemoptysis	님 님			
Chest pain	<u> </u>	Sputum		. <i>C</i> :	Nasal discharge				
Signs Wheeze	Yes No □ □	<i>Sign</i> Stridor	Yes N		Yes No				
Nasal flaring	HH	Crepitation	ᅠ, 片片	Lower chest indr Accesary muscle	·				
UNDERLYING MEI		•	<u>''                                   </u>	Accessity muscle	use 🔲 🗀				
Condition									
Lonaldon			an Vac N	a Canditian V	ac No Condition	Vac Na			
	Yes No				Tes No Condition	Yes No □ □			
COPD		Bronchitis	; <u> </u>	Diabetes	Hypertension				
COPD Chronic renal dise	ase 🔲	Bronchitis Malignand	s	Diabetes Heart disease	☐ Hypertension☐ ☐ Asthma				
COPD Chronic renal dise IMMUNOCOMPRO	ase DMISED CO	Bronchitis Malignand DNDITION:	cy	Diabetes [ Heart disease [	Hypertension				
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION	ase CO	Bronchitis Malignand ONDITION: ENT AND IN	cy	Diabetes [ Heart disease [ CON	☐ Hypertension☐ ☐ Asthma				
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da	ase DMISED CO	Bronchitis Malignand ONDITION: ENT AND IN	cy	Diabetes  Heart disease  O  DIAGNOSIS:	Hypertension Asthma ther:				
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION	DMISED CO  TREATM  THE TREATM	Bronchitis Malignand ONDITION: ENT AND IN	S	Diabetes  Heart disease  O  DI  DIAGNOSIS:  ETIOLOGY IDENTIFI	Hypertension Asthma ther:				
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN	ase DMISED COI, TREATM Inte:/	Bronchitis Malignand ONDITION: ENT AND IN	S	Diabetes  Heart disease  O  DI  DIAGNOSIS:  ETIOLOGY IDENTIFI	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO				
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment	ase DMISED COI, TREATM Inte:/	Bronchitis Malignanc ONDITION: ENT AND IN/	cy	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Treatment	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO//  Yes No Treatment				
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics	DMISED CO I, TREATM Inte:/ IOSIS: ITION: YES / I	Bronchitis Malignand DNDITION: ENT AND IN/ NO Treatment Ventilatio	cy	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: Treatment Antivirals	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO/  Yes No Treatment Steroids	Yes No			
COPD Chronic renal dise IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen	DMISED CO I, TREATM Inte:/ IOSIS: TION: YES / I Yes No Yes No	Bronchitis Malignand DNDITION: ENT AND IN/ NO Treatment Ventilatio CPAP	yes / NO  NVESTIGATI  t Yes !  n	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: Treatment Antivirals Bronchodilators	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO//  Yes No Treatment Steroids Other:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA: OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation finding	ase	Bronchitis Malignand DNDITION: ENT AND IN/ NO Treatment Ventilatio CPAP	yes / NO  NVESTIGATI  T Yes !  T Yes !	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO// Yes No Treatment Steroids Other: (leukocyte count):	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukocom	DMISED CO I, TREATM Inte:/ IOSIS: ION: YES / I Yes No III IIII	Bronchitis Malignanc DNDITION: ENT AND IN/ NO Treatment Ventilatio CPAP atocrit: Lymphocyte	t Yes In	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%):	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO/  Yes No Treatment Steroids Other: (leukocyte count):	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%):	DMISED CO  I, TREATM  Inte:/  IOSIS:  ITION: YES / I  Yes No  Graph Graph  Ings: Haema  Ings: Haema  Ings: Haema  Ings: Eosin	Bronchitis Malignanc DNDITION: ENT AND IN/ NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%):	t Yes ! n	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: Io Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%): elet (Thrombocyte) co	Hypertension Asthma  Dther:  ED: ECTED COURSE: YES / NO //  Yes No Treatment Steroids Other: (leukocyte count): (leukocyte count): Neutrophils (Sount: ESR:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA: OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoco Basophils (%): Investigation detai	DMISED CO I, TREATM Ite:/ IOSIS: TION: YES / I Yes No Yes No III IIII IIIII IIIIIIIIIIIIIIIIIIIII	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	t Yes ! n	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: IO Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%): elet (Thrombocyte) coes (findings):	Hypertension Asthma Other:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin	ase	Bronchitis Malignanc DNDITION: ENT AND IN/ NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): K ray: Yes	t Yes I n	Diabetes Heart disease Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: IO Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%): elet (Thrombocyte) coes (findings):	Hypertension Asthma  Dther:  ED: ECTED COURSE: YES / NO //  Yes No Treatment Steroids Other: (leukocyte count): (leukocyte count): Neutrophils (Sount: ESR:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA: OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	YES / NO  NVESTIGATI  YES / NO  VESTIGATI  YES / NO  NO  RRING AGEN	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  IO Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%): elet (Thrombocyte) co es (findings): ther investigation detailed.	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoco Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	YES / NO  NVESTIGATI  YES / NO  VESTIGATI  YES / NO  NO  NO  RRING AGEN  Abel	Diabetes Heart disease Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: IO Treatment Antivirals Bronchodilators Hb: WBC Monocytes (%): elet (Thrombocyte) coes (findings):	Hypertension Asthma Other:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findir Differential Leukoc Basophils (%): Investigation detai Blood culture findir SPECIMEN INFORI Specimen type 1. BAL/ETA/	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	YES / NO  NVESTIGATI  YES / NO  VESTIGATI  YES / NO  NO  RRING AGEN	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Io Treatment Antivirals Bronchodilators WBC Monocytes (%): elet (Thrombocyte) co es (findings): ther investigation details	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	YES / NO	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Io Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoco Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	t Yes I n	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Io Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findir Differential Leukoc Basophils (%): Investigation detai Blood culture findir SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	YES / NO	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Io Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera 5 Convalescent	ase	Bronchitis Malignand DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	t Yes I n	Diabetes Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date:  Io Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera 5 Convalescent sera	DMISED CO  J. TREATM  Inte:/  IOSIS:  TION: YES / I  Yes No  Dags: Haema  yet count: I  Collection  Collection  Collection	Bronchitis Malignanc DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte nophil (%): ( ray: Yes	t Yes I n	Diabetes Heart disease Heart disease  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: Io Treatment Antivirals Bronchodilators WBC Monocytes (%): elet (Thrombocyte) coes (findings): ther investigation details  CY  Specimen ID	Hypertension Asthma  Other:  ED: ECTED COURSE: YES / NO //  Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: ESR:	Yes No			
COPD Chronic renal dise. IMMUNOCOMPRO HOSPITALIZATION da DIFFERENTIAL DIAGN ATYPICAL PRESENTA OUTCOME: Discharge Treatment Antibiotics Oxygen Investigation findin Differential Leukoc Basophils (%): Investigation detai Blood culture findin SPECIMEN INFORI Specimen type 1. BAL/ETA/ 2.TS/NPS/NS 3. Blood in EDTA 4. Acute sera 5 Convalescent	DMISED CO I, TREATM Ite:/ IOSIS: TION: YES / Ite / Death / Yes No	Bronchitis Malignanc DNDITION: ENT AND IN/  NO Treatment Ventilatio CPAP atocrit: Lymphocyte aphil (%): ( ray: Yes   ROM REFER on date La	t Yes I I I I I I I I I I I I I I I I I I I	Diabetes Heart disease Heart disease  CODN  DIAGNOSIS: ETIOLOGY IDENTIFI UNUSUAL / UNEXP OUTCOME date: IO Treatment Antivirals Bronchodilators Hb:	Hypertension Asthma Other:  ED: ECTED COURSE: YES / NO  .// Yes No Treatment Steroids Other: (leukocyte count): Neutrophils (Sount: Neutrophils (Sount: Signature Services)  Distriction of the count of the	Yes No			

## ICMR- National Institute of Virology, Pune Specimen Referral Form for 2019 Novel Coronavirus (2019-nCoV)

Name of the patient:	Age:yearsmonth	ıs
Note: Please ensure that the case definition some Please encircle the correct response (Y	•	
<u>CASE D</u>	<u>EFINITION</u>	
1. Severe Acute Respiratory Illness (SARI), v	vith	
<ul><li>history of fever</li></ul>		YES / NO
<ul><li>cough</li></ul>		YES / NO
requiring admission to hospital		YES / NO
WITH		VEC / NO
no other etiology explains the clip (aliabians should also be glort).	· · · · · · · · · · · · · · · · · · ·	YES / NO
(clinicians should also be alert	าเอ เทย possibility oj ents who are immunocompromised);	
AND	nts who are illimitatiocompromisea),	
any of the following		
<ul> <li>A history of travel to Wuhan, Hub</li> </ul>	pei Province China	
in the 14 days prior to symptom o	nset.	YES / NO
<ul> <li>the disease occurs in a health car</li> </ul>		
_	nvironment where patients with	
	tions are being cared for, without re	_
place of residence or history of	or travei or unexpected clinical course, especi	YES / NO
·	e treatment, without regard to place	•
	en if another etiology has been ident	
fully explains the clinical presenta		YES /NO
2. Individuals with acute respiratory illness of	of any degree of severity who,	
within 14 days before onset of illness, had	l any of the following exposures:	
<ul> <li>close physical contact with a conf</li> </ul>	firmed case of nCoV infection, while	that
patient was symptomatic;		YES / NO
<ul> <li>a healthcare facility in a country value</li> <li>been reported;</li> </ul>	where hospital associated nCoV infe	ctions have YES / NO
<ul> <li>direct contact with animals (if animals)</li> </ul>	mal source is identified) in countries	s where the
nCoV is known to be circulating in	n animal populations or where huma	an
infections have occurred as a resu	ult of presumed zoonotic transmission	
		YES / NO
* To be added once/if animal source is identi	fied as a source of infection	
EMAIL ID OF THE HEALTH AUTHORITY (FOR SENDING	THE REPORT):	
Name of Doctor: H	lospital Name/address:	
Phone/mobile number:	ignature and date:	



### Specimen Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus (2019-nCoV)

Fitle: Specimen Collection, Packaging and Transport Guidelines for 2019 Novel Coronavirus (2019-nCoV)

SOP number: ICMR-NIV/2019-nCoV/Specimens\_02
Prepared by: Dr. Y.K. Gurav Date: 25/01/2020
Reviewed by: Dr. V. Potdar Date: 25/01/2020
Approved by: Dr. P. Abraham Date: 25/01/2020

#### Scope:

To be used by the Government health authorities/ hospitals/ clinicians/ laboratories planning to collect appropriate clinical samples as indicated for diagnosis of 2019-nCoV.

#### **Purpose:**

This document describes the information for collection, packaging and transport of clinical specimens to Influenza group at ICMR-National Institute of Virology (NIV), Pune, Maharashtra for diagnosis of 2019 Novel Coronavirus (2019-nCoV)

#### Responsibilities:

- The clinician should decide necessity for collection of clinical specimens for laboratory testing of 2019-nCoV only after following the case definition as given by the health authorities, Government of India.
- Appropriate clinical sample need to be collected by laboratory personnel/ health care worker trained in specimen collection in presence of clinician.
- By following all biosafety precautions and using personal protective equipment's (PPEs), clinical samples need to be sent to designated laboratory (ICMR-NIV, Pune) by following standard triple packaging.

#### Selection of patient:

Any person who presents with Severe Acute Respiratory Illness (SARI), AND any one of the following i.e. a history of travel from Wuhan, China in the 14 days prior to symptoms onset; disease in healthcare worker working in an environment of SARI patients; unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment; should be urgently investigated. Updated case definition need to be followed as per MOHFW, Govt of India which is available on the website www.mohfw.gov.in

#### Specimen collection details:

(Adapted from the WHO guidelines on 2019-nCoV):

Specimen type	Collection materials	Transport to laboratory	Storage till testing	Comment
# Nasopharyngeal and oropharyngeal swab	Dacron or polyester flocked swabs*	4 °C	≤5 days: 4 °C >5 days: -70 °C	The nasopharyngeal and oropharyngeal swabs should be placed in the same tube to increase the viral load.
Bronchoalveolar lavage	sterile container*	4 °C	≤48 hours: 4 °C >48 hours: −70 °C	There may be some dilution of pathogen, but still a worthwhile specimen
Tracheal aspirate, nasopharyngeal aspirate or nasal wash	sterile container*	4 °C	≤48 hours: 4 °C >48 hours: −70 °C	Not applicable
Sputum	sterile container	4 °C	≤48 hours: 4 °C >48 hours: −70 °C	Ensure the material is from the lower respiratory tract
Tissue from biopsy or autopsy including from lung	sterile container with saline	4 °C	≤24 hours: 4 °C >24 hours: −70 °C	Autopsy sample collection preferably to be avoided
#Serum (2 samples – acute and convalescent)  Serum separator tubes (adults: collect 3-5 ml whole blood)		4 °C	≤5 days: 4 °C >5 days: –70 °C	Collect paired samples:  • acute – first week of illness  • convalescent – 2 to 3 weeks later
# Whole Blood (5 ml)	Blood in EDTA Vial	4 °C	≤5 days: 4 °C	Not applicable

<sup>\*</sup>For transport of samples for viral detection, use VTM (viral transport medium) containing antifungal and antibiotic supplements. Avoid repeated freezing and thawing of specimens. # Priority specimens. Other specimens need to be sent as per the clinical condition of the patient

#### Specimen labelling and processing:

- Personal protective equipment's (apron, hand gloves, face shield, N95 Masks etc.) need to be used and all biosafety precautions should be followed so as to protect individuals and the environment.
- Proper labelling (name/age/gender/specimen ID) need to be done on specimen container and other details of sender (name/address/phone number) on the outer container by mentioning "To be tested for 2019-nCoV"
- For any queries, the nodal officer from ICMR-NIV Pune (Dr Yogesh K. Gurav, Scientist E) may be contacted (Phone 020-26006290/ 26006390; Email: gurav.yk@gmail.com/gurav.yk@gov.in) and need to be informed in advance before sending specimens to ICMR-NIV, Pune.



## Specimen Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus (2019-nCoV)

#### **Requirements for Clinical Samples Collection, Packaging and Transport**


1. Sample vials and Virus Transport Medium (VTM)



2. Adsorbent material (cotton, tissue paper), paraffin, seizer, cello tape



3. A leak-proof secondary container (e.g., ziplock pouch, cryobox, 50 mL centrifuge tube, plastic container)



4. Hard-frozen Gel Packs



5. A suitable outer container (e.g., thermocol box, ice-box, hard-board box) (minimum dimensions: 10 x 10 x 10 cm)





#### **Procedure for Specimen Packaging and Transport**

1. Use PPE while handling specimen



2. Seal the neck of the sample vials using parafilm




3. Cover the sample vials using absorbent material



4. Arrange primary container (vial) in




5. Placing the centrifuge tube inside a zip-lock pouch




6. Placing the zip-lock pouch inside a sturdy plastic container and seal the neck of the container



Note: Sample vials can also be placed inside a zip-lock pouch, covered in absorbent material and secured by heatsealing or rubber bands. Then, the zip-lock pouch







7. Using a hard card-board box as an outer container and placing the secondary container and the gel packs



8. Placing the completed Specimen Referral Form (available on www.niv.co.in) and request letter inside a leak-proof, zip-lock pouch



9. Securing the zip-lock pouch with the Specimen Referral Form on the outer container



10. Attaching the labels:

- Senders' address, contact number; Consignee's address/contact number;
- Biological substance-Category B;
- 'UN 3373'; Orientation label, Handle with care



#### Documents to accompany:

1) Packaging list/proforma Invoice 2) Air way bill (for air transport) (to be prepared by sender or shipper) 3) Value equivalence document (for road/rail/sea transport) [ Note: 1. A vaccine-carrier/ice-box can also be used as an outer container 2. The minimum dimensions of the outer container should be  $10 \times 10 \times 10$  cm (length x width x height)]

#### **Routing of samples:**

- Clinical specimens, official documents and Specimen request forms for testing of 2019-nCoV need to be sent to the ICMR-NIV address (The Director, ICMR-National Institute of Virology, 20-A, Dr Ambedkar Road, Pune, Maharashtra, Pin: 411001).
- For shipment-related queries/information, kindly contact Dr Sumit Bharadwaj (Scientist B, Influenza Group) on email: sumitduttbhardwaj@gmail.com, phone 020-26006290/26006390

#### ANNEXURE III



### ICMR - NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES

Contact: 033 2370 5533/4478/0448; 033 2353 7469; Ext. 121/190 Email: vrdln.niced@gmail.com

#### কী করবেন:

- স্বাস্থ্যবিধি মেনে জীবন যাপন করুন।
- সাবান দিয়ে নিয়মিত হাত ধোয়া অভ্যাস করুন।
- হাঁচি এবং কাশির সময় মৢখ ঢেকে রাখৢন।
- হাত নােংরা থাকলে কলের জলে সাবান দিয়ে হাত ধয়ে নিন।
- হাতে দৃশ্যমান ময়লা না থাকলেও অ্যালকোহল জাতীয় স্যানিটাইজার বা সাবান দিয়ে হাত পরিষ্কার করুন।
- টিস্যু ব্যবহারের পর সাথে সাথে ব্যবহৃত টিস্যুগুলি বন্ধ ডাস্টবিনে ফেলুন।
- ভিড় এড়িয়ে চলুন।
- জ্বর, সর্দি, কাশি আক্রান্ত ব্যক্তিদের থেকে কমপক্ষে ১ মিটার দূরত্ব বজায় রাখুন।
- অসুস্থ ব্যক্তি বা তার পরিবেশের সংস্পর্শে এলে হাত ধুয়ে নিন।
- জ্বর, সর্দি, কাশিতে আক্রান্ত হলে মেডিকেল মাস্ক পরে নিন এবং অবিলম্বে চিকিৎসকের সঙ্গে যোগাযোগ করুন।

#### কী করবেন না:


- যদি আপনি জ্বর, সর্দি, কাশি অনুভব করেন তাহলে অন্যদের খুব কাছাকাছি যাবেন না।
- যত্রতর থুতু ফেলবেন না।
- অকারণে চোখ, নাক, মুখে হাত দেবেন না।
- একবার ব্যবহারযোগ্য মাস্ক পুনরায় ব্যবহার করবেন না।
- সুস্থ ব্যক্তিদের মেডিক্যাল মাস্ক ব্যবহারের কার্যকারিতা সম্পর্কে কোন প্রমাণ পাওয়া যায় নি।
- জীবিত জন্তুজানোয়ারের খামার বা বাজার এড়িয়ে চলুন।
- কাঁচা বা অর্ধসিদ্ধ মাংস খাবেন না।
- অযথা আতঙ্ক সৃষ্টিকারী খবর বা সোশ্যাল মিডিয়ায় পাওয়া ভিডিওর সত্যতা যাচাই না করে
   শেয়ার করবেন না।


বিশদ তথ্যের জন্য পশ্চিমবঙ্গ সরকারের স্বাস্থ্যমন্ত্রকের হেল্পলাইন নম্বরে (24X7) যোগাযোগ করুন।

000-<del>2</del>08\$-<del>2</del>600

\*\*\*\*









# Protect yourself and others! Follow these Do's and Don'ts





Practice frequent hand washing. Wash hands with soap and water or use alcohol based hand rub. Wash hands even if they are visibly clean



Cover your nose and mouth with handkerchief/tissue while sneezing and coughing



Throw used tissues into closed bins immediately after use



See a doctor if you feel unwell (fever, difficult breathing and cough). While visiting doctor wear a mask/cloth to cover your mouth and nose



If you have these signs/symptoms please call State helpline number or Ministry of Health & Family Welfare's 24X7 helpline at 011-23978046



**Avoid participating** in large gatherings



Have a close contact with anyone, if you're experiencing cough and fever



Touch your eyes, nose and mouth



Spit in public

# Together we can fight Coronavirus


# For further information:

Call at Ministry of Health, Govt. of India's 24X7 control room number +91-11-2397 8046

Email at ncov2019@gmail.com







# कोरोनायरस (COVID-19)



# — खुद रहें सुरक्षित, दूसरों को रखें सुरक्षित — क्या करें और क्या ना करें

क्या करें 🛇



बार-बार हाथ धोएं। जब आपके हाथ स्पष्ट रूप से गंदे न हों, तब भी अपने हाथों को अल्कोहल - आधारित हैंड वॉश या साबुन और पानी से साफ करें



छींकते और खांसते समय, अपना मुंह व नाक टिशू/रूमाल से ढकें



प्रयोग के तुरंत बाद टिशू को किसी बंद डिब्बे में फेंक दें



अगर आपको बुखार, खांसी और सांस लेने में कठिनाई है तो डॉक्टर से संपर्क करें। डॉक्टर से मिलने के दौरान अपने मुंह और नाक को ढंकने के लिए मास्क/कपड़े का प्रयोग करें



अगर आप में कोरोना वायरस के लक्षण हैं,तो कृपया राज्य हेल्पलाइन नंबर या स्वास्थ्य मंत्रालय की 24X7 हेल्पलाइन नंबर 011-23978046 पर कॉल करें



भीड़-भाड़ वाली जगहों पर जाने से बचें



यदि आपको खांसी और बुखार का अनुभव हो रहा हो, तो किसी के साथ संपर्क में ना आयें



अपनी आंख, नाक या मुंह को ना छूयें



सार्वजनिक स्थानों पर ना थूकें

क्या न करें 🗙

# हम सब साथ मिलकर कोरोनावायरस से लड़ सकते हैं

# अधिक जानकारी के लिए

स्वास्थ्य एवं परिवार कल्याण मंत्रालय भारत सरकार के 24x7 हेल्पलाइन नं. +91-11-2397 8046 पर कॉल करें या ई-मेल करें ncov2019@gmail.com